徳島大学 教育・研究者情報データベース(EDB)

1. 宮﨑 由道

   役割	任意
   貢献度	任意
   学籍番号	推奨

2. 佐藤 健太

   役割	任意
   貢献度	任意
   学籍番号	推奨

3. (英) Koizumi Hidetaka / (日) 小泉 英貴

   役割	任意
   貢献度	任意
   学籍番号	推奨

4. 佐光 亘

   役割	任意
   貢献度	任意
   学籍番号	推奨

5. 浅沼 光太郎

   役割	任意
   貢献度	任意
   学籍番号	推奨

6. 梶 龍兒

   役割	任意
   貢献度	任意
   学籍番号	推奨

(英) [New medications for dystonia].

(日) ジストニアの新規薬物治療

(英) Although there are some newly-developed options to treat dystonia, its medical treatment is not always satisfactory. Zolpidem, an imidazopyridine agonist with a high affinity to benzodiazepine receptor subtype 1, has been reported to improve clinical symptoms of dystonia in some cases. We conducted an open-label study to assess the efficacy of zolpidem in 34 patients with primary dystonia patients, The Burke Fahn Marsden Dystonia Rating Scale (BFMDRS) scores in the patients were decreased from 7.2 ± 7.9 to 5.5 ± 5.0 after zolpidem therapy (P=0.042). Next we evaluated 55 patients with primary and secondary dystonia, 16 of 55 patients (29%) responded to zolpidem, and secondary dystonia, particularly post-traumatic dystonia, was more responsive than primary dystonia (5 of 11 [46%] vs 11 of 44 [25%]). The efficacy of zolpidem was comparable to that of other oral medications in our previous study; 33 of 89 dystonia patients (37%) responded to trihexyphenidil, 13 of 53 (25%) responded to clonazepam, and 4 of 21 (19%) responded to baclofen. In conclusion, our large scale study suggested that zolpidem may be a therapeutic option for dystonia, particularly post-traumatic dystonia.

1. (英) Article.Affiliation: Department of Clinical Neuroscience, The University of Tokushima Graduate School.

2. (英) Article.PublicationTypeList.PublicationType: English Abstract

3. (英) Article.PublicationTypeList.PublicationType: Journal Article